Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

Chromogranin A Human ELISA

  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antibody
  • Other names:Pituitary secretory protein I , CgA, SP-I, CHGA
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RSCYK070R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Competitive ELISA, Immobilized antibody

Applications

Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Urine, Saliva

Sample Requirements

25 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.14–33.33 pmol/ml

Intra-assay (Within-Run)

Plasma sample: 10.13 - 13.26 %
Saliva sample: 8.15-12.84 %

Inter-assay (Run-to-Run)

Plasma sample: 11.57-15.33 %
Saliva sample: 12.42 - 14.22 %

Spiking Recovery

Plasma sample: 126.02 %
Saliva sample: 96.6 %

Summary

Research topic

Oncology

Summary

Chromogranin A (CgA) is an acidic secretory protein consisting of 439 amino acids in human. The protein is found in a wide variety of hormone and neurotransmitter storage vesicles, and it is known be co-stored and co-released with catecholamines from adrenal medulla and sympathetic neuronal vesicles during exocytosis. O’Conner and Bernstein have first reported radioimmunological measurement of CgA in human plasma under conditions of physiologic, pharmacologic and pathologic alteration of sympathoadrenal function. Accumulated data, thereafter, have confirmed high concentrations of plasma or serum CgA measured by radioimmunoassay (CgA-like immunoreactivity: CgA-LI) in patients with neuroendocrine and endocrine tumors, especially in those with pheochromocytoma, anterior pituitary tumors and rectal and prostatic carcinoma. On the other hand,
Nakane et al. recently discovered that CgA-LI exists in saliva, the concentration of which elevates rapidly under psychosomatic stress even prior to the elevation of salivary cortisol level. Subsequently, Kanno et al. presented an evidence for autonomic control of submandibular CgA-LI secretion in the anaesthetized rat. Most of the reported measurement of CgA by radioimmunoassay utilized native CgA antigens (full or partial length) and antibodies against the native proteins. On the other hand, Yanaihara et al. provided a novel radioimmunoassay system for estimation of CgA-LI level in human plasma with use of synthetic human CgA (344-374) and antibody raised against the synthetic peptide. Nakane et al. also used the assay system in their work on human salivary CgA as mentioned above. CgA molecules contain 9-10 sites of basic amino acid pairs (Arg-Arg, Lys-Arg, etc.), which are generally accepted as the proteolytic processing sites. In fact, the sequences corresponding to CgA-derived peptides having some biological activities, such as β-granin, pancreastatin and parastatin, in CgA molecules are all preceded and followed by basic amino acid pairs. However, it is also known that in the adrenal medulla which is the major site of CgA production, CgA is found to exist predominantly in large molecular forms, supporting the least processing of CgA in adrenal chromaffin cells. In addition, it was shown that there is no rapid degradation of the protein within the blood stream.

References to Product

References

  • Blaschko H., Comiline RS., Schneider FH., Silver M. and Smith AD. (1967) Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature.215, 58-59
  • Fischer-Colbrie R., Lassmann H., Hang C. and Winkler H. (1985) Immunological studies on the distribution of chromogranin A and B in endocrine and nervous tissues. Neuroscience. 16, 547-555
  • Konnecki DS., Benedum UM., Gerdesh HH. and Huttner WB. (1987) The primary structure of human chromogranin A and pancreastatin. J. Biol. Chem. 262, 17026-17030 4. Mouland AJ., Bevan S., White JH. and Hendy GN. (1994) Human chromogranin A gene. Molecular cloning, structural analysis, and neuroendocrine cell-specific expression. J. Biol. Chem. 269, 6918-6926
  • Nishikawa Y., Li J., Futai Y., Yanaihara N., Iguchi K., Mochizuki T., Hoshino M. and Yanaihara C. (1998) Region-specific radioimmunoassay for human chromogranin A. Biomed. Res. 19, 245-251
  • O'Connor DT. (1983) Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regul. Pept. 6, 263-280
  • Yanaihara N., Nishikawa Y., Hoshino M., Mochizuki T., Iguchi K., Nagasawa S., Li J., Futai Y., Kanno T., Yanaihara H., Murai M. and Yanaihara C. (1998) Evaluation of region-specific radioimmunoassays for rat and human chromogranin A: measurement of immunoreactivity in plasma, urine and saliva. In The Adrenal Chromaffin Cell: Archetype and Exemplar od Cellular Signalling in Secretory Control (ed. Kanno T., Nakazato Y. and Kumakura K.) Hokkaido University Press, Sapporo, Japan, pp. 305-313
  • Wu JT., Astill ME., Liu GH. and Stephenson RA. (1998) Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients. J. Clin. Lab. Anal. 12, 20-25
  • Yarkac FU, Gokturk O, Demir O. Effect of non-surgical periodontal therapy on the degree of gingival inflammation and stress markers related to pregnancy. J Appl Oral Sci. 2018;26:e20170630. Published 2018 Jul 19. doi:10.1590/1678-7757-2017-0630
Related Products Documents